Oasmia Pharmaceutical AB hereby issues a notification that the Company has submitted a Form F-3 to SEC which is a required document in case the Company would need to do a financial transaction in the US during the coming three years. SEC has 30 days to respond to the document before it goes live. The document is not connected to a specific transaction. Oasmia has done this in regard to the veterinary division.
Notes to editors:
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).
Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia
This information is information that Oasmia Pharmaceutical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.45 CET on May 2, 2018.
Attachment
- PR Notis F3 ENG 180502 (https://prlibrary-eu.nasdaq.com/Resource/Download/a70531ba-c788-4304-bd54-7f0c00ce1c99)
